Newsletter Subscription

Enter Name and Email

13 February 2014 - Just published: Commentary on antipsychotics with potential neuroprotective action

Although atypical antipsychotics are commonly prescribed to treat psychosis in schizophrenia and other disorders, they fail to substantially improve cognitive impairment. The present Commentary discusses a potential strategy to improve cognition by stimulating adult neurogenesis in the hippocampus, a brain region that is part of an altered circuitry that underlies aspects of cognitive impairment in schizophrenia. In particular, activation of serotonin 5-HT1A receptors increase adult neuronal proliferation in the dentate gyrus, a part of the hippocampus. Atypical antipsychotics, such as clozapine and aripiprazole, exhibit different levels of 5-HT1A receptor partial agonism and may, therefore, differentially elicit hippocampal adult neurogenesis.

It is suggested that sustained treatment of schizophrenia patients with antipsychotics that include a 5-HT1A agonist component could be a promising strategy to favor improvement in hippocampal-dependent memory processes.

Adrian Newman-Tancredi has long-standing experience in the neurobiology of serotonergic systems. For more information, Contact.


Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT1A receptor activation.
Schreiber R, Newman-Tancredi A.
Neurobiol Learn Mem. 2014 Jan 11. pii: S1074-7427(13)00271-2. doi: 10.1016/j.nlm.2013.12.015. [Epub ahead of print]